Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bipolar I Disorder

Bipolar I Disorder

Part of Bipolar Disorder

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bipolar I Disorder

42 trials tracked for Bipolar I Disorder: 26 in phase 3 or 4 and 11 with published results. The most-cited published study has 131 citations.

42Trials tracked
26Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 4 Phase 3 22 Phase 2 11 Phase 1 2 Other / NA 3
  1. Phase 3 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients Completed · 131 cited
  2. Phase 3 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed · 119 cited
  3. Phase 3 Sensoril(Ashwaganhda)for Bipolar Disorder Completed · 115 cited
  4. Phase 3 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed · 36 cited
  5. Phase 4 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed · 29 cited
  6. Phase 4 The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Completed · 18 cited
Show 36 more trials
  1. Phase 3 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Completed · 15 cited
  2. Phase 3 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed · 10 cited
  3. Phase 3 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed · 10 cited
  4. Phase 3 Staccato Loxapine in Agitated Patients With Bipolar Disorder Completed · 10 cited
  5. Phase 3 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Completed · 6 cited
  6. Phase 4 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed
  7. Phase 4 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed
  8. Phase 3 Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex Completed
  9. Phase 3 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Completed
  10. Phase 3 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Completed
  11. Phase 3 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Completed
  12. Phase 3 A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Completed
  13. Phase 3 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features Completed
  14. Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  15. Phase 3 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed
  16. Phase 3 A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  17. Phase 3 A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  18. Phase 3 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed
  19. Phase 3 Risperdal Consta for Bipolar Disorder Completed
  20. Phase 3 A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode Completed
  21. Phase 2 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain Completed
  22. Phase 2 Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder Completed
  23. Phase 2 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Completed
  24. Phase 2 Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Completed
  25. Phase 2 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode Completed
  26. Phase 2 Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder Completed
  27. Phase 2 Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder Completed
  28. Phase 2 Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System Completed
  29. Phase 2 A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder Completed
  30. Phase 2 Gabapentin for Bipolar & Cannabis Use Disorders Completed
  31. Phase 2 Treating Smokers With Mental Illness Completed
  32. Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1) Completed
  33. Phase 1 A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020) Completed
  34. N/A iTBS in Bipolar I Depression Completed
  35. N/A Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study Completed
  36. N/A A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Bipolar I Disorder: what the trials found

Several antipsychotic agents have demonstrated efficacy in managing manic symptoms for Bipolar I Disorder. Cariprazine showed significant reductions in Young Mania Rating Scale (YMRS) scores at week 3 6 and week 16 8, as well as improvements in Clinical Global Impression-Severity (CGI-S) scores 6. Olanzapine was associated with significant reductions in YMRS scores [3, 4] and HAMD scores 4. Brexpiprazole demonstrated changes in YMRS scores at week 3 [16, 17], while Lurasidone showed a reduction of -1.0 in YMRS total score by week 12 18.

Long-term management and maintenance are supported by various formulations. IM Depot Aripiprazole significantly extended the time to recurrence of any mood episode compared to placebo 5 and improved CGI-BP-S (Mania) scores 5. Oral Aripiprazole also showed a reduction in CGI-BP severity for mania 21. Staccato Loxapine demonstrated significant improvements in Clinical Global Impression-Improvement (CGI-I) scores and reductions in the PANSS Excited Component (PEC) score after a single dose compared to placebo 11.

Weight gain is a noted outcome in some trials; for example, ALKS 3831 was associated with significant increases in body weight at week 12 9. Olanzapine was evaluated regarding BMI changes over 52 weeks, which did not reach statistical significance 3.

Recent results — preliminary, needs further review

  • Ketamine Hydrochloride was evaluated in a Phase 4 trial for Bipolar I Disorder 2.

For the clinician treating this condition

  • Cariprazine and Olanzapine are supported by evidence for reducing manic symptoms as measured by YMRS scores [3, 4, 6, 8].
  • IM Depot Aripiprazole and oral Aripiprazole provide established options for managing mania and preventing mood episode recurrence [5, 21].
  • Staccato Loxapine showed rapid improvement in clinical global impression and excited components after a single dose 11.

AI synthesis of 10 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Unipolar mania prevalence in patients with bipolar type I disorder is 21.1%
Psychiatry Meta-analysis
Unipolar mania prevalence in patients with bipolar type I disorder is 21.1% About one in five people with bipolar disorder experience mania
This meta-analysis of 35 independent samples indicates a pooled prevalence of unipolar mania (UM) in adults with bipolar type I disorder of …
New data shows that over 20% of adults with bipolar type I disorder experience unipolar mania, highlighting a need for better clinical aware…
Jul 18, 2026
FDA Approves Lamotrigine Tablets (lamotrigine) for Epilepsy and Bipolar Disorder Maintenance
Neurology FDA Approval
FDA Approves Lamotrigine Tablets (lamotrigine) for Epilepsy and Bipolar Disorder Maintenance The FDA has approved a drug called lamotrigine for epilepsy and bipolar disorder treatment
Lamotrigine tablets were approved as adjunctive therapy for partial-onset seizures, PGTC seizures, and Lennox-Gastaut syndrome in patients a…
The FDA has approved lamotrigine to help control seizures in children as young as two and maintain mood stability for adults with bipolar di…
FDA Apr 14, 2026
FDA Approves Lamotrigine for Adjunctive Therapy in Epilepsy and Maintenance in Bipolar I Disorder
Neurology FDA Approval
FDA Approves Lamotrigine for Adjunctive Therapy in Epilepsy and Maintenance in Bipolar I Disorder FDA approves lamotrigine, a medicine for epilepsy and bipolar disorder
Lamotrigine is approved for adjunctive therapy of partial-onset seizures, PGTC seizures, and seizures of Lennox-Gastaut syndrome in patients…
The FDA officially approves lamotrigine for epilepsy and bipolar disorder, confirming a long-used treatment option for adults and children a…
FDA Apr 2, 2026

Research across Bipolar Disorder

Related studies from across the Bipolar Disorder family.

Childhood adversity linked to reduced prefrontal gray matter in psychotic and bipolar disorders
Psychiatry Meta-analysis
Childhood adversity linked to reduced prefrontal gray matter in psychotic and bipolar disorders Childhood adversity linked to brain changes in psychotic and bipolar disorders
This meta-analysis of 3056 participants found significant negative associations between childhood adversity and gray matter volume in prefro…
New data shows that childhood trauma is linked to specific shrinkage in parts of the brain for people with psychotic and bipolar disorders.
medRxiv Jul 20, 2026
New 27-item screening tool developed for mental disorders in Indonesian prisons
Psychiatry Guideline
New 27-item screening tool developed for mental disorders in Indonesian prisons New screening tool helps identify mental health issues in prisons
This guideline describes the development of a 27-item, eight-domain screening tool for mental disorders among inmates in Indonesia, based on…
A new 27-item tool aims to help identify depression, anxiety, and other mental disorders among people in Indonesian prison systems.
Frontiers Jul 14, 2026
Heterogeneous ASD phenotypes and inadequate sensory criteria necessitate more robust diagnostic assessment standards
Psychiatry Sys. Review
Heterogeneous ASD phenotypes and inadequate sensory criteria necessitate more robust diagnostic assessment standards New research highlights two distinct types of autism spectrum disorder
This narrative review examines the diagnostic validity, phenotypic heterogeneity, and assessment methodologies for Autism Spectrum Disorder …
Current diagnostic tools may miss many people with autism because they do not account for different ways the condition presents in daily lif…
Frontiers Jul 9, 2026
Repetitive transcranial magnetic stimulation addresses various mental disorders including depression, bipolar disorder, and schizophrenia
Oncology Sys. Review
Repetitive transcranial magnetic stimulation addresses various mental disorders including depression, bipolar disorder, and schizophrenia Repetitive Transcranial Magnetic Stimulation Shows Potential for Mental Disorders
This narrative review synthesizes the therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) for conditions such as depr…
New research reviews how magnetic stimulation may help manage conditions like depression, bipolar disorder, and autism by affecting brain pl…
Frontiers Jul 8, 2026
Neuronavigation and connectivity guided targeting in rTMS may improve outcomes for bipolar disorder
Psychiatry Sys. Review
Neuronavigation and connectivity guided targeting in rTMS may improve outcomes for bipolar disorder Brain mapping may help patients with bipolar disorder find relief
This narrative review examines repetitive transcranial magnetic stimulation (rTMS) for patients with bipolar disorder and major depressive d…
New research suggests that using specific brain maps can help doctors better target treatments for bipolar disorder and depression.
Frontiers Jul 2, 2026
Meta-analysis reveals shorter telomeres in bipolar disorder versus healthy control populations across large sample sizes
Psychiatry Meta-analysis
Meta-analysis reveals shorter telomeres in bipolar disorder versus healthy control populations across large sample sizes Meta-analysis links bipolar disorder to shorter telomeres in a very large group
This meta-analysis of 5,639 patients with bipolar disorder and 226,358 healthy controls found significantly shorter telomere lengths. The as…
A massive analysis of nearly 60,000 people found that those with bipolar disorder had shorter telomeres than healthy controls.
Jun 5, 2026
Bipolar disorder is associated with a 3.65-fold higher risk of Parkinson's disease in six cohort studies
Neurology Meta-analysis
Bipolar disorder is associated with a 3.65-fold higher risk of Parkinson's disease in six cohort studies People with bipolar disorder face higher risk of developing Parkinson's disease based on recent analysis
This meta-analysis of six cohort studies evaluated the incidence of Parkinson's disease in individuals with bipolar disorder. The pooled ana…
A review of six studies found people with bipolar disorder have a much higher chance of getting Parkinson's disease. However, experts say we…
Frontiers Jun 5, 2026
Cocaine use disorder prevalence in bipolar disorder is 10.94 percent with worse clinical outcomes
Psychiatry Meta-analysis
Cocaine use disorder prevalence in bipolar disorder is 10.94 percent with worse clinical outcomes One in ten people with bipolar disorder also struggles with cocaine use
This systematic review and meta-analysis of 6,150,881 individuals with bipolar disorder found a pooled overall prevalence of cocaine use dis…
A large review found that 11 percent of people with bipolar disorder also have cocaine use disorder, a number that jumps to 46 percent in sp…
Jun 1, 2026
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
Psychiatry Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Diffusion tensor imaging shows lower fractional anisotropy in bipolar disorder white matter tracts
Psychiatry Meta-analysis
Diffusion tensor imaging shows lower fractional anisotropy in bipolar disorder white matter tracts Bipolar Brain Wiring Shows Clear Damage in Key Emotional Pathways
This systematic review and meta-analysis of diffusion tensor imaging studies compared 5,372 individuals with bipolar disorder to 6,240 healt…
Brain scans reveal consistent white matter damage in bipolar disorder, especially in tracts that regulate emotion and connect brain hemisphe…
May 1, 2026
Meta-analysis finds decreased GDNF levels in bipolar disorder but high heterogeneity limits conclusions
Psychiatry Meta-analysis
Meta-analysis finds decreased GDNF levels in bipolar disorder but high heterogeneity limits conclusions Brain chemical levels differ in bipolar disorder compared to healthy people
This meta-analysis of 825 patients with bipolar disorder (BD) and 885 healthy controls found significantly lower circulating GDNF levels in …
A large review found lower levels of a specific brain chemical in people with bipolar disorder. This difference was clear even when comparin…
May 1, 2026
Meta-analysis reviews psychosis prevalence in bipolar disorder patients across 285 studies
Psychiatry Meta-analysis
Meta-analysis reviews psychosis prevalence in bipolar disorder patients across 285 studies Psychosis common in bipolar disorder, review finds
This meta-analysis reviews data from 285 studies regarding the prevalence of psychosis and psychotic symptoms in patients with bipolar disor…
Nearly half of people with bipolar disorder experience psychosis, and 8% also have schizophrenia, a review of 285 studies finds.
May 1, 2026